ANVS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Stats
Today's Volume	329 953
Average Volume	228 085
Market Cap	149.75M
EPS	$0 ( 2024-04-01 )
Next earnings date	( $-0.870 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.18
ATR14	$0.0650 (0.48%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-20	White Mark K.	Buy	1 990	Common Stock
2023-11-20	Mccarthy Reid	Buy	0	Common Stock
2023-11-20	Hoffman Michael B	Buy	163 880	Common Stock
2023-11-20	Maccecchini Maria-luisa	Buy	40 970	Common Stock
2023-11-20	Hagopian Henry Iii	Buy	820	Common Stock

INSIDER POWER
89.99
Last 98 transactions
Buy: 4 567 241 \| Sell: 3 252 094

Volume Correlation

Long: 0.02 (neutral)

Short: -0.59 (weak negative)

Signal:(67.429) Neutral

Annovis Bio Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Annovis Bio Inc Correlation - Currency/Commodity

-0.31
( neutral )

-0.45
( neutral )

0.00
( neutral )

-0.06
( neutral )

0.50
( weak )

-0.37
( neutral )

Annovis Bio Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-6.23

Q4	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-2.33

Q3	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.630

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.070

Financial Reports:

No articles found.

Annovis Bio Inc

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.